silybin has been researched along with Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Amawi, H; Fetcenko, A; Hussein, N; Karthikeyan, C; Manivannan, E; Narayana Moorthy, NSH; Tiwari, AK; Trivedi, P | 1 |
| Capasso, D; Di Fabio, G; Di Gaetano, S; Lembo, A; Pagano, R; Romanucci, V; Zarrelli, A | 1 |
| Cai, H; Huo, M; Li, L; Wang, H; Yin, T; Zhang, P; Zhang, Y; Zhou, J | 1 |
| Aggarwal, D; Barwal, TS; Iqubal, A; Jain, A; Kaur, G; Kumar, M; Mittal, S; Parashar, G; Parashar, NC; Sak, K; Savla, R; Sharma, AK; Tuli, HS; Upadhyay, SK; Varol, M | 1 |
| Bosch-Barrera, J; Menendez, JA; Queralt, B | 1 |
| Baradaran, B; Jahanafrooz, Z; Mokhtarzadeh, A; Motamed, N; Rinner, B | 1 |
| Agarwal, R; Deep, G | 2 |
| Siegel, AB; Stebbing, J | 1 |
| Hagelgans, A; Menschikowski, M; Nacke, B; Siegert, G; Zamaraeva, M | 1 |
| Wang, Q; Wang, Y; Zhang, D; Zhang, L | 1 |
| Blagg, BS; Forsberg, LK; Hall, JA | 1 |
| Bosch-Barrera, J; Menendez, JA | 1 |
| Cheung, CW; Gibbons, N; Johnson, DW; Nicol, DL | 1 |
| Gao, Y; He, D; Li, L; Zeng, J | 1 |
| Barroso-Aranda, J; Contreras, F; McCarty, MF | 1 |
| Agarwal, R; Raina, K | 1 |
| Chamulitrat, W; Stremmel, W; Thongphasuk, P | 1 |
11 review(s) available for silybin and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance.
Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Polyphenols; Silybin | 2021 |
Targeting STAT3 with silibinin to improve cancer therapeutics.
Topics: Antineoplastic Agents; Antioxidants; Drug Resistance, Neoplasm; Humans; Liver Diseases; Neoplasms; Radiation Tolerance; Silybin; Silymarin; STAT3 Transcription Factor | 2017 |
Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator.
Topics: Animals; Apoptosis; Autophagy; Cell Cycle; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; Flavonolignans; Humans; MicroRNAs; Neoplasms; Signal Transduction; Silybin | 2018 |
Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.
Topics: Animals; Antioxidants; Humans; Neoplasms; Silybin; Silymarin; Translational Research, Biomedical; Tumor Microenvironment | 2013 |
Recent advances in the nanotechnology-based drug delivery of Silybin.
Topics: Antioxidants; Crystallization; Evidence-Based Medicine; Humans; Liver Diseases; Macromolecular Substances; Materials Testing; Molecular Conformation; Nanocapsules; Neoplasms; Silybin; Silymarin; Surface Properties; Suspensions; Treatment Outcome | 2014 |
Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Phosphorylation; Silybin; Silymarin; STAT3 Transcription Factor | 2015 |
Silibinin--a promising new treatment for cancer.
Topics: Antineoplastic Agents, Phytogenic; Drug Screening Assays, Antitumor; Humans; Neoplasms; Plant Extracts; Silybin; Silybum marianum; Silymarin; Treatment Outcome | 2010 |
Targeting silibinin in the antiproliferative pathway.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell Proliferation; Clinical Trials as Topic; Drug Delivery Systems; Flavonoids; Humans; Models, Biological; Neoplasms; NF-kappa B; Phytotherapy; Receptor Protein-Tyrosine Kinases; Signal Transduction; Silybin; Silybum marianum; Silymarin; STAT Transcription Factors | 2010 |
Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.
Topics: Animals; Antioxidants; Humans; Neoplasm Metastasis; Neoplasms; Signal Transduction; Silybin; Silybum marianum; Silymarin | 2010 |
Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytotoxins; Female; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Silybin; Silymarin | 2007 |
8 other study(ies) available for silybin and Neoplasms
| Article | Year |
|---|---|
Design and discovery of silybin analogues as antiproliferative compounds using a ring disjunctive - Based, natural product lead optimization approach.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Membrane Potential, Mitochondrial; Molecular Docking Simulation; Neoplasms; Silybin; Silymarin; Tubulin; Tubulin Modulators | 2017 |
Phosphodiester Silybin Dimers Powerful Radical Scavengers: A Antiproliferative Activity on Different Cancer Cell Lines.
Topics: Antioxidants; Cell Line; Neoplasms; Quercetin; Silybin; Silymarin | 2022 |
Co-delivery of silybin and paclitaxel by dextran-based nanoparticles for effective anti-tumor treatment through chemotherapy sensitization and microenvironment modulation.
Topics: Cell Line, Tumor; Dextrans; Humans; Nanoparticles; Neoplasms; Paclitaxel; Prospective Studies; Silybin; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Milk thistle: early seeds of potential.
Topics: Animals; Clinical Trials as Topic; Humans; Neoplasms; Phytotherapy; Silybin; Silybum marianum; Silymarin | 2013 |
Silibinin down-regulates expression of secreted phospholipase A2 enzymes in cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Neoplastic Stem Cells; Phospholipases A2, Secretory; RNA Isoforms; Signal Transduction; Silybin; Silymarin; Sp1 Transcription Factor; Tumor Stem Cell Assay | 2014 |
Alternative approaches to Hsp90 modulation for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Catechin; Drug Discovery; HSP90 Heat-Shock Proteins; Humans; Models, Molecular; Neoplasms; Novobiocin; Silybin; Silymarin | 2014 |
Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy.
Topics: Angiogenesis Inhibitors; Anthracyclines; Cardiac Glycosides; Cell Hypoxia; DNA Topoisomerases, Type I; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Intracellular Signaling Peptides and Proteins; Neoplasm Invasiveness; Neoplasms; NF-kappa B; Protein Serine-Threonine Kinases; Salicylic Acid; Silybin; Silymarin; TOR Serine-Threonine Kinases | 2010 |
Potent direct or TNF-alpha-promoted anticancer effects of 2,3-dehydrosilybin: comparison study with silybin.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Drug Therapy, Combination; Flow Cytometry; Humans; Necrosis; Neoplasms; Silybin; Silymarin; Time Factors; Tumor Necrosis Factor-alpha | 2008 |